Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MCLA-145 · 1 trial · 3 indications
| Arm | Type | Description |
|---|---|---|
| MCLA-145 | EXPERIMENTAL | In Part 1, the dose escalation phase, patients with advanced or recurrent/metastatic solid tumors or B-cell lymphomas will receive escalating doses of MCLA-145 (either Q2W for those patients in treatment at the time of Amendment #4 or Q3W with Amendment #4 approval). Treatment will be with MCLA-145 (monotherapy) for Group A, or in combination with pembrolizumab for Group B, until MTD or RDE is reached. In Part 2, the expansion phase, participants with advanced or metastatic solid tumors will receive intravenous infusion of MCLA-145 either in monotherapy (Group A) or in combination with pembrolizumab (Group B) at the recommended phase II dose every 3 weeks. The duration of each treatment cycle is 21 days |
| Group B Combination Treatment | EXPERIMENTAL | Patients in Group B will be treated with MCLA-145 in Combination with pembrolizumab 200mg Q3W. |
| Name | Type | Description |
|---|---|---|
| MCLA-145 | DRUG | full-length IgG1 bispecific antibody specifically targeting PD-L1 and CD137 |
| Pembrolizumab (Keytruda) | DRUG | Group B patients will be treated in combination with MCLA-145 and pembrolizumab 200mg Q3W. |
Inclusion Criteria: * Histologically or cytologically confirmed advanced or recurrent/metastatic solid tumors or B-cell lymphomas, that are considered non-amenable to surgery or other curative treatments or procedures (if applicable) * Measureable disease per RECIST v1.1 or Lugano Criteria * Easter...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| GE Healthcare Technologies Inc. | GEHC | 1 | PHASE1 | GEH200520/ GEH200521- Part A |
| Zimmer Biomet Holdings, Inc. | ZBH | 1 | - | Undisclosed |
| Ascentage Pharma Group International Unsponsored ADR | AAPG | 1 | PHASE1 | Olverembatinib |
MCLA-145 is an investigational bispecific antibody being studied for the treatment of advanced cancer, including solid tumors and B-cell lymphoma in adults. It is currently in Phase 1 clinical development and is not yet approved by regulatory authorities.
MCLA-145 is a bispecific antibody designed to engage two distinct targets on immune cells to enhance anti-tumor activity. The specific molecular targets are not disclosed in the available information, but the drug is being evaluated for its ability to treat advanced malignancies.
MCLA-145 is being developed by Merus N.V., a biopharmaceutical company. Merus is listed on the NASDAQ under the ticker symbol MRUS.
MCLA-145 is in Phase 1 clinical development. A Phase 1 study of MCLA-145 in patients with advanced or metastatic malignancies has been completed, and the drug remains investigational.
MCLA-145 has been studied in a Phase 1 clinical trial with the identifier NCT03922204, titled 'A Study of Bispecific Antibody MCLA-145 in Patients With Advanced or Metastatic Malignancies.' The trial enrolled 72 participants and was conducted in the United States, Belgium, Netherlands, and Spain.